Lanreotid Amdipharm (Lanreotide Acetate)

Lanreotide acetate is a synthetic analogue of somatostatin. It binds to somatostatin receptors, especially SSTR2 and SSTR5, inhibiting the secretion of growth hormone, IGF‑1, and various gastrointestinal hormones, which helps control hormone‑driven disease activity.

The specific dose and dosing interval of Lanreotid Amdipharm are determined by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Patients should follow the prescriber’s instructions.

Safety data for lanreotide acetate in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lanreotid Amdipharm (lanreotide acetate) is similar to other long‑acting somatostatin analogues such as octreotide LAR. Both suppress hormone secretion, but lanreotide is administered as a deep‑subcutaneous injection and may have a slightly different dosing schedule, which can influence convenience and patient preference.

Lanreotid Amdipharm should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

The medication is given by deep subcutaneous injection, typically in the abdominal wall, thigh, or upper arm. Administration is performed by a healthcare professional or a trained patient following aseptic technique and the prescriber’s instructions.

Serious risks include gallbladder disease (such as gallstones or biliary sludge), hyperglycemia or new‑onset diabetes, acute pancreatitis, and severe allergic reactions. Patients should be monitored for these events and instructed to report any concerning symptoms promptly.

Lanreotid Amdipharm is contraindicated in patients with known hypersensitivity to lanreotide acetate or any of the formulation excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease.